PCF 2021 VL

The Prostate Cancer Foundation Team Science TACTICAL Awards - Howard Soule

Details
Howard Soule joins Charles Ryan as they discuss a new Prostate Cancer Foundation (PCF) TACTICAL Team Science Award as part of a broader novel T herapy AC celeration T o I ntercept CA ncer L ethality (TACTICAL) campaign. These larger team science awards will consist of $3MM or more team science awards seeking new therapies for treatment-resistant and intercepting issues of treatment resistance. One...

NCCN Guidelines On PSMA Molecular Imaging - Tanya Dorff

Details
Alicia Morgans and Tanya Dorff, discuss the updates to the NCCN guidelines since the approval of PSMA PET CT molecular imaging agents. They discuss new guidance based on the FDA-approved indications in the labels for the use of molecular imaging agents for detecting prostate cancer when PSA levels are still relatively low and when PSA levels are rising. Biographies: Tanya B. Dorff, MD., is an asso...

The History of Radiopharmaceuticals in Prostate Cancer - Neil Bander

Details
Neil Bander joins Alicia Morgans in a conversation on the history of radiopharmaceuticals, their development, and where they may ultimately fit in the prostate cancer treatment landscape. Dr. Bander reviewed how these agents were developed starting roughly 18 - 20 years ago targeting PSMA with the antibody developed at Cornell, called J591, the first antibody to the extracellular domain of PSMA. H...

Improving Health Equity and Reducing Disparities in Prostate Cancer Care – Kosj Yamoah

Details
Kosj Yamoah joins Alicia Morgans in discussing improving health equity, reducing disparities in prostate cancer care, and how the Prostate Cancer Foundation (The PCF) supports this initiative. There are differences in the way prostate cancer inequity occurs, directly from the incidence, the development of the disease itself, the presentation of the disease when a patient is seen in the clinic, the...

Bispecific T-cell Engager (BiTE®) in Development for Treatment of Advanced Prostate Cancer - Oliver Sartor

Details
Oliver Sartor joins Alicia Morgans and discusses the evolving landscape of BiTE ® technology applied to prostate cancer therapy. BiTE is a bispecific T-cell engaging antibody that binds on PSMA and CD3 on the T cells to activate the T cells. Bispecific T-cell engagers are a novel approach to tumor immunotherapy. They discuss the current clinical trials landscape and what is maybe on the horizon fo...

Mentoring Women in Science - David Quinn

Details
Alicia Morgans and David Quinn discuss the promotion of women through the ranks of medical oncology ensuring they have opportunities within the prostate cancer research and clinical arena. Biographies: David Quinn, MBBS, Ph.D., FR, Associate Professor of Medicine, Section Head, GU Oncology, Division of Cancer Medicine and Blood Diseases, Keck School of Medicine USC Alicia Morgans, MD, MPH , Genito...

Exercise for Improved Survivorship in Prostate Cancer - Christina Dieli-Conwright

Details
In this UroToday discussion, Christina Dieli-Conwright joins Alicia Morgans in a conversation on exercise for patients and the future of exercise research for men with prostate cancer. The conversation begins with Dr. Dieli-Conwright reviewing the evidence we have to date that supports exercise for improving quality of life and mental health. She highlights the multifactorial benefits of exercise...

Women in Science and The Prostate Cancer Foundation - Amina Zoubeidi

Details
Amina Zoubeidi joins Alicia Morgans in a conversation on the evolution of her career and how the Prostate Cancer Foundation (The PCF) played a pivotal role in supporting her research initiatives and the collaboration and friendships that result from the Women in Science Program at the PCF Annual Retreat. PCF consistently demonstrates a commitment to women scientists by supporting their research. T...

Lifestyle Interventions to Reduce Prostate Cancer Risk - Lorelei Mucci

Details
Lorelei Mucci joins Alicia Morgans in a conversation on exercise and nutrition in cancer care. Dr. Mucci provides an overview of the impact of lifestyle and nutrition on cancer and disease risk. She highlights specific types of dietary patterns that are associated with a lower risk of cancer overall, specifically more aggressive forms of prostate cancer or cancers that ultimately will become fatal...

Ongoing Clinical Trials Evaluating The Efficacy of Targeted Radioligand Therapy - Shahneen Sandhu

Details
Shahneen Sandhu joins Alicia Morgans in a conversation about targeted radioligand therapy in prostate cancer. They discuss several upcoming and ongoing trials with Lutetium. Biographies: Shahneen Sandhu, MD, Ph.D., MBBS, FRACP, Associate Professor, Consultant Medical Oncologist and Researcher, Peter MacCallum Cancer Centre, Melbourne, Australia Alicia Morgans, MD, MPH , Genitourinary Medical Oncol...
email news signup